Reviva reports first quarter 2024 financial results and recent business highlights

– gained alignment with u.s. food and drug administration (fda) on brilaroxazine clinical trials for new drug application (nda) submission in schizophrenia –
RVPH Ratings Summary
RVPH Quant Ranking